Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit 

Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.

Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments

Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy 

The PARP inhibitor shows durable clinical benefits in HRD+ patients with advanced disease reinforcing the importance of testing for BRCA mutations and/or HRD status.

In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy 

Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers

Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access

In this era of precision medicine, affordable profiling is essential  

The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022